GeoVax Labs, Inc. — 2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020, compared with 2019. This is an annual report, not a standalone fourth-quarter report. GeoVax is a clinical-stage biotechnology company developing vaccines and immunotherapies using its GV-MVA-VLP platform; it had no product sales.
Financial results and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Grant and collaboration revenue | $1.824 million | $1.176 million |
| Research and development expense | $2.444 million | $1.911 million |
| General and administrative expense | $2.196 million | $1.638 million |
| Operating loss | $2.817 million | $2.372 million |
| Net loss | $2.958 million | $2.371 million |
| Net cash used in operating activities | $2.751 million | $1.398 million |
- Revenue increased 55%; R&D expense rose 28%, while G&A expense rose 34%. Net loss widened approximately 25%.
- At year-end, cash and cash equivalents were $9.884 million, total assets $10.394 million, working capital $9.425 million, and total liabilities $825,047. Working capital was a $1.569 million deficit at year-end 2019.
- Financing activities provided $12.508 million in 2020, principally from a September public offering that generated approximately $11.2 million net. The company reported no product revenue and expects continuing losses; product-level gross margins are not applicable.
- Year-end notes payable totaled approximately $198,000, including the $170,200 PPP loan and the remaining GRA note. The $1.2 million principal amount of convertible debentures, plus accrued interest, converted to equity in September 2020.
Business developments and outlook
- GeoVax began COVID-19 vaccine development in January 2020 and had designed four candidates, then in preclinical animal testing. A $299,927 NIAID Phase I SBIR grant was awarded in January 2021.
- HIV programs included completed Phase 1/2a testing of GOVX-B11 and planned HVTN 132 enrollment in late 2021. UCSF’s combination-therapy trial using the company’s vaccine began enrollment in August 2020; GeoVax expected its vaccine to be added to AGT’s Phase 1 program in 2021.
- Other programs included preclinical candidates for Ebola, Sudan, Marburg, Lassa fever, Zika and malaria, and early-stage cancer immunotherapies. Development priorities may shift because of limited capital and staffing; some programs depend on additional grant or partner funding.
- Management said cash resources and existing government funding commitments were expected to support planned operations into 2023. Further financing would be needed to materially advance programs and continue operations beyond that horizon; equity, debt, grants and partnerships were potential sources, with no assurance of availability.
- The February 2021 stock offering generated approximately $9.4 million net proceeds. January–February 2021 warrant exercises generated a further approximately $3.2 million net. These subsequent proceeds are not included in 2020 year-end cash.
Risks, contingencies and unusual items
- All candidates remain investigational; development, clinical success, regulatory approval and commercialization are uncertain. The company has a history of losses and an accumulated deficit of $45.8 million.
- GeoVax relies on third-party manufacturers, clinical networks and research collaborators, has no commercial manufacturing or sales infrastructure, and disclosed a shortage of vaccine manufacturing capacity that could affect candidate production.
- Outstanding warrants and future financing could dilute shareholders. At December 31, 2020, the filing reported 3.60 million warrants outstanding; the common-stock offering also included warrants.
- The PPP loan forgiveness application had not been processed as of the report date. The company also disclosed approximately $190,000 in vendor and subcontractor purchase commitments due in 2021, of which $165,500 was expected to be grant-reimbursable.
- No material legal proceedings were reported. The auditor gave an unqualified opinion on the financial statements and identified equity transactions as a critical audit matter. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the auditor did not provide an opinion on internal control effectiveness.
Most important facts to verify
- Whether reported cash runway into 2023 remains supportable after operating cash use, planned development spending and subsequent financing.
- Progress, enrollment timing and funding for HVTN 132, the UCSF trial and the planned GeoVax contribution to AGT’s trial.
- COVID-19 candidate preclinical results, grant spending and any evidence supporting the company’s proposed differentiation.
- Availability and cost of third-party manufacturing, and whether grant-funded programs receive continued funding.
- Current share count, warrant exercises and remaining potential dilution, including the impact of the 2021 offering and warrant activity.